Expert Interview
Looking at the clinical landscape for prevention of major cardiovascular events, including an in depth discussion about the phase 2 data of Milvexian, an anticoagulation medication in development by Bristol Myers and Janssen Pharmaceuticals
Ticker(s): BMY, JNJInstitution: Beats Cardiology
- Cardiologist; Specialty and Interest in Heart Attack & Stroke Prevention – Bale-Doneen trained – aggressive management of coronary risk factors, including inflammation, cholesterol, high blood pressure, smoking cessation, diet, and obesity
- Attended Medical School at Texas Tech University; Internship and Residency in Internal Medicine at Baylor University Medical Center in Dallas, TX; Fellowship in Cardiology at Baylor University Medical Center in Dallas, TX
- Medical Director of Cardiology, Baylor Scott & White Medical Center – Plano: 2013-2021
- Manages 30 patients on anti-coagulation medications for the prevention of stroke, pulonary embolism, and atrial fibrillation
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
